Clinical Trials Logo

Solid Carcinoma clinical trials

View clinical trials related to Solid Carcinoma.

Filter by:

NCT ID: NCT03221400 Recruiting - Gastric Cancer Clinical Trials

PEN-866 in Patients With Advanced Solid Malignancies

Start date: August 29, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Protocol PEN-866-001 is an open-label, multi-center, first-in-human Phase 1/2a study evaluating PEN-866 in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.

NCT ID: NCT03129139 Recruiting - Breast Cancer Clinical Trials

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelideā„¢ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors

Minnelide 101
Start date: October 10, 2017
Phase: Phase 1
Study type: Interventional

A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelideā„¢Capsules given daily for 21 days followed by 7 days off schedule in patients with Advanced Solid Tumors

NCT ID: NCT01312701 Recruiting - Solid Carcinoma Clinical Trials

Study of Blood Immune Cells in Cancer Patients Compared to Controls

Start date: March 2011
Phase: N/A
Study type: Observational

Tumors have a systemic immune modifying effect. They affect the immune system similarly to states of chronic inflammation and these effects can: - be monitored through analysis of nk t and myeloid cells mainly through studies of the zeta chain but also through other means - may be decreased following effective anticancer therapy - may even be used to study the effectiveness of anticancer therapy - are important to monitor if the investigators plan on formulation of systemic immune therapy Thus immumonitoring of systemic blood cells may turn out to be an important prognostic and predictive factor in many cancer types